Health · Medical Research · 1 day ago
Rapamycin improved brain blood flow in adults with an Alzheimer’s risk gene
Researchers studied rapamycin, a drug used in transplant medicine, in healthy adults aged 45 to 65.
The study included people with and without APOE4, a gene variant linked to a higher risk of Alzheimer’s disease.
Participants took a low dose of the drug every day for four weeks.
Brain blood flow improved only among those with APOE4, with the greatest improvement seen in women carrying the variant.
Reduced blood flow can occur years before memory problems in people with APOE4, so researchers are investigating whether it could be an early sign to target.
The study was small and brief, and it did not show that rapamycin protects memory or prevents Alzheimer’s.
Researchers need further evidence to learn whether the drug could help reduce risk over time.
A four-week study found that low-dose rapamycin improved brain blood flow in healthy adults carrying the APOE4 Alzheimer’s risk variant.
The study included adults ages 45 to 65, none of whom had Alzheimer’s symptoms.
Participants without APOE4 did not show the reported improvement in brain blood flow.
Female participants with APOE4 saw the greatest improvement, according to researcher Ai-Ling Lin.
The study does not establish whether rapamycin can protect memory or prevent Alzheimer’s disease.
- Who
- Healthy adults ages 45 to 65, including carriers and non-carriers of APOE4, took part in the study.
- What
- Daily low-dose rapamycin for four weeks was linked to improved brain blood flow in APOE4 carriers.
- When
- The four-week study was reported in an article published on 11 October 2026.
- Where
- The study was led by Ai-Ling Lin of the University of Missouri’s School of Medicine.
- Why
- Researchers investigated whether rapamycin could affect early brain changes associated with Alzheimer’s risk.
This story does not have two clearly opposing sides.
We also found that females with APOE4 saw the greatest improvement in brain blood flow, which is significant given that nearly two-thirds of people with Alzheimer’s are women.
This research is an example of precision medicine, as we work to identify who can benefit from this drug the most.
If we can slow down aging in the brain for those people most at risk, maybe we can reduce the risk of them developing Alzheimer’s disease.
The study was published in the Journal of Cerebral Blood Flow & Metabolism.
SciTechDaily reported the study’s findings.
- Drug
- Rapamycin, taken at a low dose daily
- Study duration
- Four weeks
- Participants
- Healthy adults ages 45 to 65
- Risk variant
- APOE4
- Finding
- Improved brain blood flow was reported only in participants carrying APOE4
Sources
Related news
UK doctors transplant frozen testicular tissue to try to restore fertility
Pope Leo to have surgery to remove an early-detected lung nodule
Early lung nodule removal can offer high chance of cure, oncologist says
Digital tools improve asthma treatment adherence in children
Early statin use linked to lower dementia risk in people with type 2 diabetes
Navigation and reminders may boost colonoscopy after positive stool tests
Study finds women report more frequent and intense pain than men
Pope Leo XIV to have surgery to remove early-stage lung nodule
Study links APOE4 to scarring around brain blood vessels
Large Study Finds Sudden Body Changes Around Menopause
